RMTI vs. AADI, NBRV, JAGX, CLNN, APLM, NXTC, BOLT, IMRX, IRIX, and CALC
Should you be buying Rockwell Medical stock or one of its competitors? The main competitors of Rockwell Medical include Aadi Bioscience (AADI), Nabriva Therapeutics (NBRV), Jaguar Health (JAGX), Clene (CLNN), Apollomics (APLM), NextCure (NXTC), Bolt Biotherapeutics (BOLT), Immuneering (IMRX), IRIDEX (IRIX), and CalciMedica (CALC).
Aadi Bioscience (NASDAQ:AADI) and Rockwell Medical (NASDAQ:RMTI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, community ranking, dividends, profitability, valuation, media sentiment and analyst recommendations.
Rockwell Medical received 290 more outperform votes than Aadi Bioscience when rated by MarketBeat users. Likewise, 57.33% of users gave Rockwell Medical an outperform vote while only 50.00% of users gave Aadi Bioscience an outperform vote.
Rockwell Medical has a net margin of -10.09% compared to Rockwell Medical's net margin of -270.04%. Aadi Bioscience's return on equity of -39.17% beat Rockwell Medical's return on equity.
Rockwell Medical has higher revenue and earnings than Aadi Bioscience. Rockwell Medical is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.
52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 23.3% of Rockwell Medical shares are owned by institutional investors. 35.8% of Aadi Bioscience shares are owned by insiders. Comparatively, 2.2% of Rockwell Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Aadi Bioscience had 6 more articles in the media than Rockwell Medical. MarketBeat recorded 6 mentions for Aadi Bioscience and 0 mentions for Rockwell Medical. Rockwell Medical's average media sentiment score of 0.48 beat Aadi Bioscience's score of 0.00 indicating that Aadi Bioscience is being referred to more favorably in the media.
Aadi Bioscience presently has a consensus target price of $24.67, indicating a potential upside of 1,063.52%. Rockwell Medical has a consensus target price of $7.00, indicating a potential upside of 343.04%. Given Rockwell Medical's higher probable upside, equities research analysts plainly believe Aadi Bioscience is more favorable than Rockwell Medical.
Aadi Bioscience has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Rockwell Medical has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500.
Summary
Rockwell Medical beats Aadi Bioscience on 11 of the 18 factors compared between the two stocks.
Get Rockwell Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for RMTI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RMTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rockwell Medical Competitors List
Related Companies and Tools
